Meta-Analysis
Copyright ©The Author(s) 2022.
World J Gastrointest Surg. Dec 27, 2022; 14(12): 1397-1410
Published online Dec 27, 2022. doi: 10.4240/wjgs.v14.i12.1397
Table 1 Included studies related data
Ref.
Publication year
Journal
Country
Study design
TaTME
LaTME
de’Angelis et al[13]2015Langenbecks Arch SurgFranceRetrospective observational study3232
Kanso et al[14]2015Dis Colon RectumFranceRetrospective observational study5134
Pontallier et al[15]2016Surg EndoscFranceRCT3834
Marks et al[16]2016Tech. ColoproctolUnited StatesRetrospective observational study1717
Lelong et al[17]2017J Am Coll SurgFranceRetrospective observational study3438
Denost et al[18]2018Surg EndoscFranceRCT5050
Mege et al[19]2018Colorectal DisFranceRetrospective observational study3434
Rubinkiewicz et al[20]2018Cancer Manag ResPolandRetrospective observational study3535
Roodbeen et al[21]2019Surg EndoscNetherlandsRetrospective observational study4141
Rubinkiewicz et al[22]2019BMC SurgPolandProspective observational study2323
Ren et al[23]2021Asian J SurgChinaProspective observational study3232
Li et al[24]2022Gastroenterol Res PractChinaProspective observational study106106
Table 2 Included studies related data
Ref.
Publication year
Age
Gender
BMI
Neoadjuvant therapy
Tumour stage
Tumour location
Distance of tumour to anal verge
de’Angelis[13]201564.91 ± 10.05 vs 67.16 ± 9.6166% vs 66%25.19 ± 3.52 vs 24.53 ± 3.19100% vs 100%I: 65.6% vs 56.3%; II: 31.3% vs 40.6%; III: 3.1% vs 3.1%Low rectum4 (2.5-5.0) vs 3.7 (2.5-5.0)
Kanso et al[14]201559 ± 11 (32-79) vs 59 ± 11 (33-82)71% vs 77%24 ± 4 (17-32) vs 24 ± 4 (15-34)80% vs 79%NRLower rectum1.6 ± 0.8 (0-3.5) vs 1.8 ± 0.9 (0-3.5)
Pontallier et al[15]201662 (39-81) vs 62 (35-82)68% vs 62%25.5 vs 24.879% vs 88%I: 21% vs 21%; II: 19% vs 14%; III: 60% vs 65%Low rectum4 (2-6) vs 4 (2-6)
Marks et al[16]201660 vs 59NR25.9 vs 26.4NRI: 29.4% vs 23.5%; II: 70.6% vs 76.5%Low rectum< 4 vs < 4
Lelong et al[17]2017NR68% vs 58%24 (18.6-45.0) vs 24.2(17.7-32.7)88.2% vs 92.1%I: 17.6% vs 23.7%; II: 70.6% vs 71.0%; III: 11.8% vs 5.3%Low rectumNR
Denost et al[18]201864 (39-82) vs 63 (31-90)74% vs 64%25.1 (17.3-33.2) vs 25.6 (18.3-38.3)78% vs 84%NRLow rectum 4 (2-6) vs 4 (2-6)
Mege et al[19]201858 ± 14 vs 59 ± 1368% vs 68%25 ± 4 vs 25 ± 385% vs 85%I: 29.4% vs 11.8%; II: 67.6% vs 82.3%; III: 43.5% vs 47.8%; IV: 2.9% vs 5.9%Low rectumNR
Rubinkiewicz et al[20]201864.3 ± 10.1 vs 60.3 ± 10.269% vs 69%26.10 ± 4.09 vs 27.10 ± 4.7188.6% vs 88.6%I: 42.9% vs 45.7%; II: 57.1% vs 54.3%Low rectum2.90 ± 1.17 vs 3.19 ± 1.47
Roodbeen et al[21]201962.5 ± 10.7 vs 66.0 ± 9.282.9% vs 78%26.7 ± 1.9 vs 26.1 ± 4.043.9% vs 43.9%I: 22.0% vs 19.5%; II: 36.6% vs 39%; III: 31.7% vs 31.7%; IV: 9.8% vs 9.8%Low rectum2.0 (0.0-4.0) vs 1.5 (0.0-3.0)
Rubinkiewicz et al[22]201960 (51-67) vs 64 (58-67)69% vs 69%26 (22.8-29.7) vs 26.5 (23.8-30.6)78.2% vs 82.6%NRLow rectum3(2-4) vs 4 (3-5)
Ren et al[23]202165.78 ± 12.37 vs 67.16 ± 10.0359.3% vs 56.2%22.87 ± 2.66 vs 23.05 ± 2.7071.8% vs 65.6%I: 34.3% vs 37.5%; II: 28.1% vs 31.2%; III: 31.2% vs 21.8%Low rectum5.53 ± 0.98 vs 5.78 ± 0.94
Li et al[24]202255 ± 12 (23-78) vs 56 ± 12 (26-79)100% vs 100%23:0 ± 2.9 vs 22:9 ± 3.2100% vs 100%NRLow rectum3.6 ± 0.9 (2.0-5.0) vs 3.8 ± 0.9 (1.4-5.0)
Table 3 Methodological quality of the observational studies assessed with the Newcastle-Ottawa scale
AuthorRepresentativeness of the exposed cohortSelection of the non-exposed cohortAscertainment of exposureDemonstration that outcome of interest was not present at start of studyComparability of cohorts on the basis of the design or analysisAssessment of outcomeWas follow-up long enough for outcomes to occurAdequacy of follow up of cohortsTotal score
de’Angelis[13], 2015*********9
Kanso et al[14], 2015*********9
Marks et al[16], 2016****-***7
Lelong et al[17], 2017********8
Mege et al[19], 2018*********9
Rubinkiewicz et al[20], 2018*********9
Roodbeen et al[21], 2019*********9
Rubinkiewicz et al[22], 2019********8
Ren et al[23], 2021*********9
Li et al[24], 2022*********9